We’ve recently returned from the very successful annual meeting of the Association for Vascular Access (www.avainfo.org). Though many hospitals have reduced the size of their IV teams or eliminated them altogether, it was obvious from last week’s gathering at the gigantic Gaylord conference center in National Harbor, Md. that there is still a substantial cohort of vascular access experts out there, working hard and deeply committed to better patient care.
One of the highlights of the conference for us was doing a focus group with Excelsior Medical, makers of the SwabCap disinfection cap for needleless IV connectors. Excelsior took the time and effort to meet with a small group of nurses to get some qualitative, very informative feedback about the vascular access challenges that nurses face.
Earlier in the month, Excelsior also teamed with AVA to cosponsor a webinar on best methods to disinfect needless connectors. The webinar is archived at http://tinyurl.com/35c6jnt.
The focus group and other feedback indicate that hospitals and vascular access nurses remain open to new and better means to achieve two goals:
1.) Complying with Joint Commission and similar protocols for cleaning needleless connectors/disinfection caps.
2.) Reducing catheter-related bloodstream infections (CRBSI, also known as a central line associated bloodstream infections or CLABSI).
Watch this space for more about the AVA conference and other new technological developments featured at the conference.
The Joint Commission will require hospitals to have a standardized protocol to disinfect catheter luer access valves, starting January 2010. In the face of that new dictum, what’s a hospital to do?
A panel pondering that question – and featuring three national vascular access experts — drew more than 100 nurses at the recent annual meeting of the Association for Vascular Access. Panelists were:
• Lynn Hadaway, M.Ed., RNC, CRNI, infusion therapy expert
• Gregory Schears, MD, Mayo Clinic
• Kelly Fugate, ND, RN, Joint Commission
The panel’s focus: Preventing Intraluminal Contamination from CRBSI’s: Complying with New Guidelines from the Joint Commission & SHEA Compendium.” The event was sponsored by Excelsior Medical, makers of the SwabCap disinfection cap for luer access valves, and moderated by Greg Dennis, of Dowling & Dennis Public Relations.
Dr. Schears led off by outlining the seriousness of catheter-related bloodstream infections, which are all too common despite years of effort aimed at eradicating these potential killers. He said it was a “logical extension” of infection control efforts to cover and disinfect valves with a cap.
Lynn Hadaway outlined a variety of studies on the issue, while Kelly Fugate explained why the Joint Commission has new National Patient Safety Goals that include the disinfection protocol requirement,..
For more on SwabCap, go to http://www.Excelsiormedical.com. Excelsior Medical is a client of Dowling & Dennis Public Relations.
We’re happy to report that even in the economic downturn, we’ve added two new clients:
* Excelsior Medical is a leading maker of prefilled catheter flush syringes. The company is also launching an exciting new technology called SwabCap™. This product promises to pioneer more effective prevention of potentially deadly catheter-related bloodstream infections.
SwabCap provides passive, verifiable disinfection of the top and threads of luer access valves. These valves are a critical part of providing IV medication and nutrition. Both the Joint Commission and SHEA/IDSA Compendium have new guidelines calling for hospitals to have a specific disinfection protocol– meaning Excelsior expects strong demand for SwabCap as part of the company’s focus on preventing intra-luminal contamination of catheters. http://www.ExcelsiorMedical.com
*Novian Health makes the Novilase™ laser ablation device to treat fibroadenomas of the breast. These non-cancerous lumps are a troubling breast health problem for many women. Novilase provides a minimally invasive alternative to surgical lumpectomy, with no scarring and less infection risk. Novilase is FDA-cleared for treating fibroadenomas. http://novianhealth.com